Literature DB >> 31958486

Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma.

Tatevik R Broutian1, Bo Jiang2, Jingfeng Li3, Keiko Akagi2, Shanying Gui3, Zhengqiu Zhou3, Weihong Xiao2, David E Symer4, Maura L Gillison5.   

Abstract

Human papillomavirus (HPV) insertions in cancer genomes have been linked to various forms of focal genomic instability and altered expression of neighboring genes. Here we tested the hypothesis that investigation of HPV insertions in a head and neck cancer squamous cell carcinoma (HNSCC) cell line would identify targetable driver genes contributing to oncogenesis of other HNSCC. In the cell line UPCI:SCC090 HPV16 integration amplified the PIM1 serine/threonine kinase gene ~16-fold, thereby increasing transcript and protein levels. We used genetic and pharmacological approaches to inhibit PIM kinases in this and other HNSCC cell lines. Knockdown of PIM1 transcripts by transfected short hairpin RNAs reduced UPCI:SCC090 viability. CRISPR/Cas9-mediated mutagenesis of PIM1 caused cell cycle arrest and apoptosis. Pharmacological inhibition of PIM family kinases decreased growth of UPCI:SCC090 and additional HNSCC cell lines in vitro and a xenograft UPCI:SCC090 model in vivo. Based on established interactions between intracellular signaling pathways and relatively high levels of gene expression in almost all HNSCC, we also evaluated combinations of PIM kinase and epidermal growth factor receptor (EGFR) inhibitors. Dual inhibition of these pathways resulted in supra-additive cell death. These data support clinical testing of PIM inhibitors alone or in combination in HNSCC.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Head and neck squamous cell carcinoma; Human papillomavirus (HPV); Molecular therapeutics; PIM serine/threonine kinases; Virus insertional mutagenesis

Mesh:

Substances:

Year:  2020        PMID: 31958486      PMCID: PMC7239795          DOI: 10.1016/j.canlet.2020.01.012

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  60 in total

Review 1.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

2.  Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.

Authors:  Maciej Szydłowski; Monika Prochorec-Sobieszek; Anna Szumera-Ciećkiewicz; Edyta Derezińska; Grażyna Hoser; Danuta Wasilewska; Olga Szymańska-Giemza; Ewa Jabłońska; Emilia Białopiotrowicz; Tomasz Sewastianik; Anna Polak; Wojciech Czardybon; Michał Gałęzowski; Renata Windak; Jan Maciej Zaucha; Krzysztof Warzocha; Krzysztof Brzózka; Przemysław Juszczyński
Journal:  Blood       Date:  2017-07-11       Impact factor: 22.113

3.  Landscape of genomic alterations in cervical carcinomas.

Authors:  Akinyemi I Ojesina; Lee Lichtenstein; Samuel S Freeman; Chandra Sekhar Pedamallu; Ivan Imaz-Rosshandler; Trevor J Pugh; Andrew D Cherniack; Lauren Ambrogio; Kristian Cibulskis; Bjørn Bertelsen; Sandra Romero-Cordoba; Victor Treviño; Karla Vazquez-Santillan; Alberto Salido Guadarrama; Alexi A Wright; Mara W Rosenberg; Fujiko Duke; Bethany Kaplan; Rui Wang; Elizabeth Nickerson; Heather M Walline; Michael S Lawrence; Chip Stewart; Scott L Carter; Aaron McKenna; Iram P Rodriguez-Sanchez; Magali Espinosa-Castilla; Kathrine Woie; Line Bjorge; Elisabeth Wik; Mari K Halle; Erling A Hoivik; Camilla Krakstad; Nayeli Belem Gabiño; Gabriela Sofia Gómez-Macías; Lezmes D Valdez-Chapa; María Lourdes Garza-Rodríguez; German Maytorena; Jorge Vazquez; Carlos Rodea; Adrian Cravioto; Maria L Cortes; Heidi Greulich; Christopher P Crum; Donna S Neuberg; Alfredo Hidalgo-Miranda; Claudia Rangel Escareno; Lars A Akslen; Thomas E Carey; Olav K Vintermyr; Stacey B Gabriel; Hugo A Barrera-Saldaña; Jorge Melendez-Zajgla; Gad Getz; Helga B Salvesen; Matthew Meyerson
Journal:  Nature       Date:  2013-12-25       Impact factor: 49.962

4.  Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas.

Authors:  M Dürst; C M Croce; L Gissmann; E Schwarz; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

5.  Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma.

Authors:  Timothy Cooper; Vincent L Biron; David Fast; Raymond Tam; Thomas Carey; Maya Shmulevitz; Hadi Seikaly
Journal:  J Otolaryngol Head Neck Surg       Date:  2015-02-24

6.  The role of PIM1/PIM2 kinases in tumors of the male reproductive system.

Authors:  Manuel Pedro Jiménez-García; Antonio Lucena-Cacace; María José Robles-Frías; Maja Narlik-Grassow; Carmen Blanco-Aparicio; Amancio Carnero
Journal:  Sci Rep       Date:  2016-11-30       Impact factor: 4.379

7.  Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.

Authors:  Maura L Gillison; Keiko Akagi; David E Symer; Weihong Xiao; Bo Jiang; Robert K L Pickard; Jingfeng Li; Benjamin J Swanson; Amit D Agrawal; Mark Zucker; Birgit Stache-Crain; Anne-Katrin Emde; Heather M Geiger; Nicolas Robine; Kevin R Coombes
Journal:  Genome Res       Date:  2018-12-18       Impact factor: 9.043

8.  Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas.

Authors:  M L Breuer; H T Cuypers; A Berns
Journal:  EMBO J       Date:  1989-03       Impact factor: 11.598

Review 9.  Pim kinases in hematological malignancies: where are we now and where are we going?

Authors:  Patrizia Mondello; Salvatore Cuzzocrea; Michael Mian
Journal:  J Hematol Oncol       Date:  2014-12-10       Impact factor: 17.388

Review 10.  EGFR-TKIs resistance via EGFR-independent signaling pathways.

Authors:  Qian Liu; Shengnan Yu; Weiheng Zhao; Shuang Qin; Qian Chu; Kongming Wu
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more
  6 in total

Review 1.  A systematic review on active sites and functions of PIM-1 protein.

Authors:  Youyi Zhao; Aziz Ur Rehman Aziz; Hangyu Zhang; Zhengyao Zhang; Na Li; Bo Liu
Journal:  Hum Cell       Date:  2022-01-09       Impact factor: 4.174

2.  Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers.

Authors:  David E Symer; Keiko Akagi; Heather M Geiger; Yang Song; Gaiyun Li; Anne-Katrin Emde; Weihong Xiao; Bo Jiang; André Corvelo; Nora C Toussaint; Jingfeng Li; Amit Agrawal; Enver Ozer; Adel K El-Naggar; Zoe Du; Jitesh B Shewale; Birgit Stache-Crain; Mark Zucker; Nicolas Robine; Kevin R Coombes; Maura L Gillison
Journal:  Genome Res       Date:  2021-12-13       Impact factor: 9.043

3.  Whole-Exome Sequencing of HPV Positive Tonsillar and Base of Tongue Squamous Cell Carcinomas Reveals a Global Mutational Pattern along with Relapse-Specific Somatic Variants.

Authors:  Andreas Ährlund-Richter; Stefan Holzhauser; Tina Dalianis; Anders Näsman; Michael Mints
Journal:  Cancers (Basel)       Date:  2021-12-24       Impact factor: 6.639

4.  Relationship between the transcriptional expression of PIM1 and local control in patients with head and neck squamous cell carcinomas treated with radiotherapy.

Authors:  Xavier León; Jacinto García; Albert Pujol; Julia de Juan; Rosselin Vásquez; Miquel Quer; Mercedes Camacho
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-06       Impact factor: 3.236

Review 5.  Immunotherapy of targeting MDSCs in tumor microenvironment.

Authors:  Hongshu Sui; Shengyi Dongye; Xiaocui Liu; Xinghua Xu; Li Wang; Christopher Q Jin; Minhua Yao; Zhaoqing Gong; Daniel Jiang; Kexin Zhang; Yaling Liu; Hui Liu; Guomin Jiang; Yanping Su
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

Review 6.  Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care.

Authors:  Haoru Dong; Xinhua Shu; Qiang Xu; Chen Zhu; Andreas M Kaufmann; Zhi-Ming Zheng; Andreas E Albers; Xu Qian
Journal:  Virol Sin       Date:  2021-06-21       Impact factor: 4.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.